methyl 4,5,6,7-tetrahydrobenzothiophene-1-carboxylate | 6435-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: methyl 4,5,6,7-tetrahydrobenzothiophene-1-carboxylate
• 英文别名: 1-Methoxycarbonyl-4.5.6.7-tetrahydro-benzothiophen；2-Methoxycarbonyl-tetrahydrobenzothiophen；4,5,6,7-tetrahydro-benzo[c]thiophene-1-carboxylic acid methyl ester；Methyl 4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylate；methyl 4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate
• CAS: 6435-72-9
• 化学式: C₁₀H₁₂O₂S
• 分子量: 196.27
• InChiKey: RYFPZWZZXKMYTC-UHFFFAOYSA-N

物化性质

• 沸点：
  118 °C(Press: 2.5 Torr)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4,5,6,7-tetrahydrobenzothiophene-1-carboxylate 在 N-甲基吗啉 、 sodium hydroxide 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 、 benzyltrimethylazanium tribroman-2-uide 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 溶剂黄146 、 乙腈 为溶剂， 反应 15.0h， 生成 dimethyl N-(3-bromo-4,5,6,7-tetrahydrobenzo[c]thienoyl)-L-glutamate
  参考文献：
  名称：

  Replacement of the 1‘,4‘-Phenylene Region in 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDATHF) by 4,5,6,7-Tetrahydrobenzo[c]thiophene and 4,5,6,7-Tetrahydroisobenzofuran Nuclei

  摘要：

  Two new analogs of DDATHF, in which the 1',4'-phenylene unit is replaced by 4,5,6,7-tetrahydrobenzo[c]thiophene and 4,5,6,7-tetrahydroisobenzofuran nuclei, have been prepared and evaluated for in vitro cytotoxicity, GARFT inhibition, and FPGS affinity as potential antitumor agents.

  DOI：

  10.1021/jo9619903
• 作为产物：
  描述：

  巯基乙酸甲酯 、 Cyclohexanone-2-carbaldehyde 在 硫酸 、 sodium methylate 作用下， 生成 methyl 4,5,6,7-tetrahydrobenzothiophene-1-carboxylate
  参考文献：
  名称：

  Replacement of the 1‘,4‘-Phenylene Region in 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDATHF) by 4,5,6,7-Tetrahydrobenzo[c]thiophene and 4,5,6,7-Tetrahydroisobenzofuran Nuclei

  摘要：

  Two new analogs of DDATHF, in which the 1',4'-phenylene unit is replaced by 4,5,6,7-tetrahydrobenzo[c]thiophene and 4,5,6,7-tetrahydroisobenzofuran nuclei, have been prepared and evaluated for in vitro cytotoxicity, GARFT inhibition, and FPGS affinity as potential antitumor agents.

  DOI：

  10.1021/jo9619903

文献信息

• Hypervalent iodine(III): selective and efficient single-electron-transfer (SET) oxidizing agent
  作者：Toshifumi Dohi、Motoki Ito、Nobutaka Yamaoka、Koji Morimoto、Hiromichi Fujioka、Yasuyuki Kita

  DOI：10.1016/j.tet.2009.10.040

  日期：2009.12

  ethers, affording the corresponding aromatic cation radicals. Since then, hypervalent iodine(III) has been utilized as a selective and efficient SET oxidizing agent that enables a variety of direct C–H functionalizations of aromatic rings in electron-rich arenes under mild conditions. We have now extended the original method to work in a series of heteroaromatic compounds such as thiophenes, pyrroles,

  1994年，我们首先确定了苯基碘（III）双（三氟乙酸盐）（PIFA）对苯基醚的单电子转移（SET）氧化能力，提供了相应的芳族阳离子自由基。从那时起，高价碘（III）已被用作一种选择性和高效的SET氧化剂，可在温和条件下在富电子芳烃中实现芳环的各种直接C–H官能化。现在，我们已经将原始方法扩展为可用于一系列杂芳族化合物，例如噻吩，吡咯和吲哚。本文总结了自本世纪初以来的调查和结果。
• THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME
  申请人：CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.

  公开号：EP3466946A1

  公开（公告）日：2019-04-10

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and applicantion of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种用作尿酸转运体（URAT1）抑制剂的噻吩，以及该噻吩在制备治疗与尿酸水平异常有关的疾病的药品中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎的药品中的应用。本发明具体涉及由式（I）代表的化合物或其药学上可接受的盐。
• Thiophene, manufacturing method thereof, and pharmaceutical application of same
  申请人：CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.

  公开号：US10829483B2

  公开（公告）日：2020-11-10

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and application of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种用作尿酸转运体（URAT1）抑制剂的噻吩，以及该噻吩在制备治疗与尿酸水平异常有关的疾病的药品中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎的药品中的应用。本发明具体涉及一种由式（I）代表的化合物或其药学上可接受的盐。
• [EN] URICOSURIC AGENT, SYNTHETIC METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] AGENT URICOSURIQUE, SON PROCÉDÉ DE SYNTHÈSE ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 一种尿酸促排剂及其合成方法和其在医药上的应用
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2021083182A1

  公开（公告）日：2021-05-06

  一类作为尿酸盐转运体(URAT1)抑制剂的尿酸促泄剂的化合物，及其在制备治疗尿酸水平异常病症药物中的应用。具体涉及式(I)所示化合物及其药学上可接受的盐。
• EP3466946
  申请人：——

  公开号：——

  公开（公告）日：——